Drug
Tegaserod clinical trials
- studies test it
- 23
- open now
- 0
- in phase 3
- 14
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2004 (13)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 13 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 14
- Phase 4
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 2
Novartis (20) · Hospital Authority, Hong Kong (2) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tegaserod is read from its arms, and is right about nine times in ten.
Testing it · 23
- Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With DyspepsiaCompletedPhase 3NovartisNCT00232089Written as Tegaserod
- Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation PatientsTerminatedPhase 4NovartisNCT00348634Written as Tegaserod
- Preference of Tegaserod vs. PEG 3350 in Patients With ConstipationCompletedPhase 4NovartisNCT00171522Written as Tegaserod and Polyethylene Glycol 3350
- Effect of Tegaserod on Gastric Emptying in Patients With Diabetic GastroparesisTerminatedPhase 4NovartisNCT00390975Written as Tegaserod
- Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.TerminatedPhase 3NovartisNCT00399659Written as Tegaserod
- Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic GastropathyTerminatedPhase 2NovartisNCT00142974Written as Tegaserod
- Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer PainTerminatedPhase 2/3NovartisNCT00365820Written as Tegaserod
- The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)TerminatedPhase 3Novartis PharmaceuticalsNCT00171431Written as Tegaserod
- Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.TerminatedPhase 3NovartisNCT00414024Written as Tegaserod
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic ConstipationTerminatedNot applicableHospital Authority, Hong KongNCT00563758Written as tegaserod
- A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)CompletedPhase 2NovartisNCT00149851Written as Tegaserod
- Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic MethodStatus unknownNot applicableHospital Authority, Hong KongNCT00563615Written as Tegaserod
- Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.CompletedPhase 3NovartisNCT00141089Written as Tegaserod
- An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic ConstipationCompletedPhase 3NovartisNCT00139568Written as Tegaserod
- Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With DyspepsiaCompletedPhase 3NovartisNCT00232024Written as Tegaserod
- The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.CompletedPhase 3NovartisNCT00171470Written as Tegaserod
- Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of DyspepsiaCompletedPhase 3NovartisNCT00232037Written as Tegaserod
- Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of DyspepsiaCompletedPhase 3NovartisNCT00232102Written as Tegaserod
- Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic ConstipationCompletedPhase 4NovartisNCT00149877Written as Tegaserod
- Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).CompletedPhase 3NovartisNCT00171418Written as Tegaserod
Codes
What other systems call tegaserod · ClinicalTrials.gg INT003972
- MeSH (NLM) C105050tegaserodConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 458VC51857TEGASERODConfirmed FDA, NLM, Wikidata
- RxNorm 139778Confirmed FDA, Wikidata
- Wikidata Q44944tegaserodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66583TegaserodConfirmed FDA, Wikidata
- DrugBank DB01079One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C105050 | tegaserod | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 458VC51857 | TEGASEROD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 139778 | — | Confirmed FDA, Wikidata |
| Wikidata | Q44944 | tegaserod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66583 | Tegaserod | Confirmed FDA, Wikidata |
| DrugBank | DB01079 | — | One source Wikidata |
Also registered as tegaserod maleate (UNII E5XNT3RF5A · RxNorm 339270).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.